HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Cancer drug doses: More is not always better
-
- Is it feasible to change the immunotherapy dose schedule for a patient in complete response?
- Mi oh mi-RNA and ... mi-too: New biomarkers for germ cell tumors Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Take a look back at the top chronic lymphocytic leukemia news from 2019
- APPs ‘integral,’ distinct part of the oncology workforce Robin M. Rosselet, DNP, APRN-CNP/CNS, AOCN
- ‘Visibility matters’ when establishing LGBTI-friendly practice for younger patients with cancer
- Penn program addresses ‘barriers and bias’ unique to women in oncology
- Light therapy could prevent cancer treatment-related oral mucositis
- Investigational blood-based assay could lead to earlier ovarian cancer detection
-
- Program seeks to improve rate of genetic testing among patients with breast cancer
- CRISPR-edited T cells appear safe for patients with cancer
- MRI studies show evidence of CAR-T neurotoxicity after clinical symptoms resolve
- CAR T-cell therapy offers benefit, reduces health care utilization for older patients with DLBCL
- Rapid precision medicine approach feasible, improves OS among older patients with AML
- Brigatinib confers durable PFS benefit in ALK-positive NSCLC
- Atezolizumab plus bevacizumab extends survival in unresectable HCC
- ‘Stay tuned:’ Neoadjuvant therapy in thyroid cancer still needs research
-
- Memorial Sloan Kettering Cancer Center oncologist receives lifetime achievement award
- Tall cell variant cutoff IDs highest-risk papillary thyroid carcinomas
- Molecular knowledge explains response in differentiated thyroid cancer
- ‘Rational combination therapies’ stand as the next step in thyroid cancer
- Tipifarnib induces responses in HRAS-mutant head and neck squamous cell carcinoma
- Psychiatric disorders, stress increase risk for cervical cancer mortality
- Childhood cancer survivors at higher risk for suicide, death from risky behavior
- Secondary surgery does not prolong survival in recurrent ovarian cancer
-
- Molecular analysis may aid in tailoring treatment for certain patients with colorectal cancer
- Addition of panitumumab to FOLFOXIRI improves response rates in colorectal cancer subtype
- Skin toxicity from anti-PD-1 therapy associated with better melanoma outcomes
- Addition of metformin to TKI therapy improves survival in EGFR-mutant lung cancer
- Pretreatment vitamin D deficiency linked to shorter survival in Hodgkin lymphoma
- Delayed surgery linked to progression, worse outcomes in ductal carcinoma in situ
- Favorable prognosis of NPM1 mutations in AML lost in patients with poor cytogenetic risk
- Oral prostate cancer therapies increase mortality risk for men with cardiovascular conditions
-
- FDA approves Adakveo to reduce pain crises from sickle cell disease
- FDA calls for boxed warning on breast implants
- FDA grants breakthrough therapy designation to Zejula for prostate cancer subtype
- FDA expands Zejula approval for gynecologic cancers
- FDA approves Calquence for chronic lymphocytic leukemia under international collaboration
- FDA grants fast track designation to T-Guard for acute graft-versus-host disease
- FDA grants orphan drug designation to Copiktra for T-cell lymphoma
- Hematologists, oncologists elected to National Academy of Medicine
-
- Samuel Waxman Cancer Research Foundation awards $1.4 million in grants
- Fred Hutchinson Cancer Research Center director to step down
- Breast surgeon to lead Duke Cancer Institute's clinical cancer genetics program